- In April 2024, The Bracco Group announced the establishment of Bracco Japan, aimed at strengthening its presence in the Japanese market. Bracco Japan will offer a wide range of products and services in the field of diagnostic imaging
- In April 2024, Curium, a global leader in nuclear medicine, revealed its agreement to acquire Eczacibasi Monrol Nuclear Product Co. (Monrol) from Eczacibasi Holding and Bozlu Group. This acquisition combines complementary geographical footprints, enhances lutetium-177 (Lu-177) capabilities, and strengthens PET and SPECT nuclear medicine infrastructure. It also supports the advancement of radionuclides and radiopharmaceutical pipelines for diagnostic and therapeutic applications
- In April 2024, Telix announced the completion of its acquisition of ARTMS Inc., a radioisotope production technology company. This includes ARTMS’ advanced cyclotron-based production platform, manufacturing facility, and rare metals stockpile. The acquisition enhances Telix's supply chain integration and regulatory control over key isotope production
- In April 2024, Clarity Pharmaceuticals signed a clinical supply agreement with NorthStar Medical Radioisotopes, LLC to produce the 67Cu-SAR-bisPSMA drug product for Phase I/II and Phase III clinical trials
- In February 2024, Lantheus Holdings, Inc. entered a collaboration agreement with the Consortium for Clarity in ADRD Research Through Imaging (CLARiTI), sponsored by the National Institute on Aging (NIA). The agreement facilitates the use of MK-6240, Lantheus’ clinical-stage F18-labeled PET imaging agent, in Alzheimer’s disease and dementia research
- In January 2024, Novartis presented Phase III trial results demonstrating that Lutathera (lutetium Lu 177 dotatate), combined with long-acting release (LAR) octreotide, reduced the risk of disease progression or death by 72% compared to high-dose octreotide LAR alone as a first-line therapy for patients with somatostatin receptor-positive (SSTR+) grade 2/3 advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs)
